A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath

Phase 1 Unknown 114 enrolled International AIDS Vaccine Initiative Brigham and Women's Hospital · collab East-West Medical Research Institute · collab George Washington University · collab Redemption Hospital · collab

RandomizedParallel-groupTriple-blindPrevention

Summary

A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Health

Timeline

Start: 2021-06-23
Primary completion: 2023-12-19
Completion: 2024-03

Publications

Malkin E, Zaric M, Kieh M, Baden LR, Fitz-Patrick D, Marini A, Yun H, Hayes P, Bromell R, Ayorinde M, Fernandez N, Varma R, Sigei F, Ward M, Pindolia H, Sewell S, Amini F, Blie J, Wilson B, Faley P, McCullough J, Tokpah F, Wisseh C, Towalid E, Hadawale S, Sayeed E, Hunt D, Keshavarzi N, Barin B, Maljkovic Berry I, Parks CL, Truter SG, Walker K, Vekemans J, Lehrman J, Engelbrecht M, Malherbe M, Laufer D, Philiponis V, Higgs E, Mutua G, Fast PE, Gupta SB; rVSVDeltaG-LASV-GPC Study Group. Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate. N Engl J Med. 2025 Nov 6;393(18):1807-1818. doi: 10.1056/NEJMoa2501073.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	rVSV∆G-LASV-GPC	Vaccine	20000 unknown	Intramuscular
Subject	rVSV∆G-LASV-GPC	Vaccine	200000 unknown	Intramuscular
Subject	rVSV∆G-LASV-GPC	Vaccine	2e+06 unknown	Intramuscular
Subject	rVSV∆G-LASV-GPC	Vaccine	2e+07 unknown	Intramuscular

A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath

Summary

Timeline

Publications

Drugs

Indications